Overview

Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Status:
Not yet recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The study is phase II, open label, clinical trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer

Phase:

Phase 2

Details

Lead Sponsor:

Yonsei University

Treatments:

Pembrolizumab